Rating Change
Guggenheim reiterated its Buy rating on Eloxx Pharmaceuticals, Inc. (OTC:ELOX) on October 28, 2026.
reiterateOTC:ELOX
Guggenheim Reiterates Buy Rating on Eloxx Pharmaceuticals, Inc. (ELOX)
Guggenheim reiterated its Buy rating on Eloxx Pharmaceuticals, Inc. (OTC:ELOX) on October 28, 2026.
At publication ·
What changed
Eloxx Pharmaceuticals, Inc. (OTC:ELOX) · reiterate
- Firm
- Guggenheim
- Rating
- Buy to Buy
- Price at event
- $13.12
- Market capitalization
- $314.0
At a glance
Key takeaways
- Guggenheim reiterated a Buy rating on Eloxx Pharmaceuticals (ELOX) on October 28, 2026, with the stock trading at $13.12.
Market Context
Eloxx Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $13.12 with a market capitalization of 314.0. The stock has gained 13339900.0% over the past 52 weeks.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Eloxx Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Eloxx Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 28, 2026 | Guggenheim | Buy | N/A |
| Oct 15, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Sep 18, 2026 | Leerink Partners | Outperform | N/A |
| Aug 24, 2026 | Guggenheim | Buy | N/A |
| Aug 20, 2026 | LUCID CAPITAL MARKETS | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ELOX Stock Page
Frequently Asked Questions
What does the Buy rating mean for ELOX?
A rating of Buy from Guggenheim reflects the analyst's outlook on Eloxx Pharmaceuticals, Inc. (OTC:ELOX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ELOX forecast page.
